Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:11:28 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Optomed Q1 2023 - Delivers as expected

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Optomed Q1 2023 - Delivers as expected

2023-05-05 15:27:00

Redeye provides an update in relation to Optomed’s Q1 2023 report. The sales amounted to EUR3.5m (EUR3.2m), and EBIT came in at EUR-1,0m (EUR-1.5), which was fairly in line with our expectations and estimates. We have chosen to only make some minor changes in our 2023e sales estimate due to the slight delay in the FDA process. Moreover, we believe there are exciting times ahead of us and reiterate our base case of EUR8.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/